Introduction
Despite the ongoing trend away from invasive ventilation toward continuous airway pressure (CPAP) in the neonatal intensive care unit, a number of patients still require ventilation. In a proportion of these patients, ventilation may become difficult because of the presence of viscous sections, resulting in areas of collapse, increased risk of pneumonia, prolonged ventilation and potential damage to lung parenchyma. 1 Pulmonary secretions attain their viscosity from the presence of extracellular DNA from degenerating polymorphonuclear lymphocytes. Recombinant human DNase (rhDNase) reduces sputum viscosity by hydrolyzing extracellular DNA, thus allowing it to flow and be easily cleared. 2 Use of rhDNase is an established pediatric therapy in patients with cystic fibrosis and has been reported in pediatric populations with bronchiolitis, respiratory syncitial virus and asthma. 3 Limited data are available regarding the use of rhDNase in the neonatal population. 4, 5 We therefore summarize our experience with this therapy in four patients over the last 2 years. This study was approved by the Royal Women's Hospital Research and Ethics Committee.
Case

Patient 1
Patient 1 was born at 25-week gestational age. She was intubated at birth, received surfactant (poractant alfa) and remained ventilated for 7 weeks. She required reintubation at 9 weeks of life for an acute deterioration associated with sepsis. Oxygenation was problematic and showed no response to high-frequency oscillatory ventilation or to a trial of nitric oxide inhalation. Endotracheal tube (ETT) secretions were copious, requiring several reintubations for tube blockage. ETT aspirate supported the growth of Enterococcus faecalis, and thus antibiotic therapy was revised appropriately. Serial chest radiographs showed extensive consolidation of both lung fields with alternating collapse of the dependent lung. At 10 weeks of life, although showing no improvement on conventional ventilation, she was subjected to a trial of 2.5-mg nebulized DNase (Pulmozyme 227 Roche, Basel, Switzerland). Her inspired oxygen concentration (FiO 2 ) decreased from 0.9 to 0.4 over a period of 5 days; during this time, minimal set tidal volumes were also weaned until day 6 of treatment when she was successfully extubated to CPAP. Repeated chest radiographs showed resolution of atelectasis after 3 days of DNase treatment.
Patient 2
Patient 2 was delivered at 25-week gestational age; he was ventilator dependent for the first 8 weeks of life. He suffered a number of episodes of presumed sepsis, and Klebsiella oxytoca and Enterobacter spp. were isolated on separate ETT aspirate cultures; these were treated with appropriate antibiotics. Serial chest radiographs showed hyperinflation, cystic lung changes and alternating collapse of the dependent lung, which varied with changes in the baby's position. At 6 weeks of life, he had worsening hypercarbia and required 100% oxygen that showed no response to a trial of high-frequency oscillatory ventilation. The patient then received a trial of 2.5-mg rhDNase that was instilled undiluted endotracheally every 8 h. Oxygenation index was 29.5 before treatment was started. This reduced to 20.9 at 24 h after DNase treatment was started. After 3 days of rhDNase treatment, the radiographic appearance of the patient's chest improved, FiO 2 was reduced to 0.35 and rhDNase was ceased. The patient's FiO 2 then returned to 0.6 and rhDNase treatment was recommenced. Over the following week, his FiO 2 remained static at 0.6, whereas other ventilation parametersFset tidal volume and peak inspiratory pressureFwere successfully weaned off. He was extubated to CPAP and was FiO 2 -weaned over the subsequent 4 weeks.
Patient 3
Patient 3 was born at 24 weeks and was ventilated from birth. He became unwell on day 4 of life owing to the infection from sepsiscausing Escherichia coli, and was therefore treated with a prolonged course of antibiotics. The patient's ventilation and FiO 2 requirements increased, requiring high-frequency oscillatory ventilation and 100% oxygen. A chest radiograph showed left-sided collapse after the preceding image had demonstrated right-sided collapse, prompting the patient to be nursed left side up. He did not respond to ventilation changes, and rhDNase treatment was commenced on day 8 of life, receiving 2.5 mg of rhDNase that was instilled endotracheally every 8 h for 5 days. On day 2 of this regimen, his FiO 2 was weaned from 0.9 to 0.45; oxygenation index decreased from 29.3 to 14.7 over the same time period; and after 4 days high-frequency oscillatory ventilation was changed to conventional ventilation. A chest radiograph taken 5 days after commencement of treatment demonstrated significant improvement in consolidation. The patient was extubated to CPAP at 9 weeks of age.
Patient 4
Patient 4 was born at 28 weeks; he was ventilated from birth until extubation to CPAP on day 6. He required reintubation at the age of 5 weeks for an episode of profound apnea. Blood cultures were negative but ETT aspirate supported the growth of Klebsiella spp. In the context of persisting right middle lobe collapse on serial chest radiographs, he was treated with antibiotics for 14 days. His FiO 2 was stable at 0.35 but the radiological abnormalities persisted. RhDNase treatment (2.5 mg, instilled endotracheally every 8 h) was commenced. There was no improvement in radiographic appearance, and ventilation requirements needed to be increased over 9 days of treatment; therefore rhDNase was discontinued. Review of the patient's chest radiographs suggested that the middle lobe collapse was secondary to the right upper lobe hyperinflation. A radiological diagnosis of right upper lobe emphysema was confirmed bronchoscopically; lobectomy was performed at 10 weeks of life and the patient was ultimately extubated to CPAP.
Discussion
The first three patients were all preterm infants with severe, end-stage respiratory failure requiring maximal ventilator support and showed radiological evidence of changing patterns of collapse and consolidation. Each patient failed to show an improvement after optimization of ventilation strategies and each of them substantially improved following rhDNase therapy. Our fourth patient's presentation differed as he remained on conventional ventilation with modest oxygen requirements; he did not respond to rhDNase and a congenital lung abnormality was subsequently identified. We did not observe any of the previously reported side effects of rhDNase (voice alteration, pharyngitis, dyspepsia or facial oedema 4 ) in any of our patients; however, we were limited by the small number of patients and by the difficulties in assessing therapy-related effects.
A small number of reports of the use of rhDNase in neonates have previously been published. El Hassan and Huysman 4 reported the use of nebulized rhDNase in three preterm patients, similar to the treatment in our first three patients. All patients had lung disease that was unresponsive to conventional strategies such as position change, suctioning and escalation of ventilator mode and settings. The rescue use of rhDNase was successful, with all showing a rapid reduction in oxygen and ventilation requirement, as well as radiographic improvement, within hours of administration. Erdeve et al. 5 also reported the use of rhDNase in 12 ventilated newborns, 10 of whom were preterm, who had not responded to conventional escalations of ventilation and had radiologically documented atelectasis and received nebulized rhDNase. Ten patients showed rapid clinical and radiological response; the two patients who did not show a rapid clinical and radiological response were subsequently administered a single dose that was instilled through ETT, resulting in recovery.
Our infants received a dosage of 2.5 mg (2.5 ml) every 8 or 12 h. Three infants received the dose directly instilled into the trachea. One patient received a nebulized dose: 2.5-mg rhDNase was diluted with normal saline to a total volume of 4 ml and nebulized using a gas flow of 8 l min À1 during ongoing ventilation. Because of the high bias flows and low tidal volumes, it is not recommended to administer nebulized therapy during high-frequency ventilation. During volume targeted ventilation mode, the nebulization may affect flow sensor function and tidal volume measurement; therefore, the flow sensor was removed and a non-volume targeted mode of ventilation was used during administration 6 in our patients. Our usual practice is to frequently suction the infant immediately after administration, in order to clear loosened secretions. Our infants tolerated both nebulized and instilled dosing well; however, there was one incidence of bradycardia and desaturation associated with rapid instillation. This responded to a period of manual intermittent positive-pressure ventilation.
In previously published reports, dose and frequency of administration differed greatly both within and between centers that use rhDNase in ventilated premature infants. Erdeve's group administered a nebulized dose of 1.25 mg (half the recommended pediatric dose) twice daily with 2 h between each dose, for up to 3 days. If this regimen failed to produce clinical improvement, a single dose of 1.25 mg was instilled endoctracheally. 5 In the report by Hendriks et al.
1 of rhDNase administration in the pediatric population, 250 mg (10% of the nebulized dose used) was administered endotracheally to ventilated patients and was still reported to yield an effect. There is no consensus on the optimum dose or means of administration in ventilated neonates.
There is a lack of randomized trials in this patient group. A recent randomized controlled trial of rhDNase in 225 infants with bronchiolitis did not identify an improvement in symptom score, duration of oxygen therapy or hospital stay in the treatment group. 7 Well-designed randomized studies, adequately powered and including appropriately selected neonates could assess whether the reported effects are therapeutic benefits or coincidental improvements and therapeutic benefit. Additional trials will potentially identify the optimal therapeutic approaches in these infants.
Conclusion
In our series, three of the four neonatal patients with end-stage respiratory failure showed clinical improvement following rhDNase therapy. These patients were noted to have problematic secretions, high ventilation requirements and radiographic collapse that varied with position. The non-responder had a congenital lung abnormality. Other case series have suggested that rhDNase may benefit selected neonatal patients. Because of the low incidence of this problem in the preterm population, a multicentre, randomized trial with this therapy could potentially ascertain its efficacy and safety.
